KPI is working with scientists, doctors, and patients to develop our autoimmune pipeline. Leveraging state-of-the-art science to create novel medicines for serious illness, KPI is focused on high-quality candidates for diseases with high unmet patient need.

PlatformTherapeutic AreaIndications DiscoveryPreclinicalPhase 1Phase 2Phase 3
Kv1.3 Inhibitor
SystemicMyositis, Cutaneous Lupus, Psoriasis, Psoriatic Arthritis
DermatologyAtopic Dermatitis, mild to moderate Psoriasis
OphthalmologyUveitis, Dry Eye Syndrome (DES), other autoimmune ocular diseases

*This program is jointly developed by KPI Therapeutics and its sister corporation Kineta, Inc.